21Jan 2021
CMTM6 Expression as a Potential Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma

CMTM6 Expression as a Potential Biomarker for Immunotherapy in Metastatic Renal Cell Carcinoma

The introduction of immune checkpoint inhibitors (ICIs) has revolutionized the treatment of metastatic renal cell carcinoma (mRCC) [1]. The expression of programmed death‐ligand 1 (PD‐L1) as assessed by immunohistochemistry (IHC) has been extensively studied as predictive biomarker for patients receiving ICIs. However, results in clinical RCC trials concerning the predictive value of PD‐L1 expression

  • #urology

Like

Save

Share